Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Feb. 20, 2025 -- The FDA has approved a new fast-acting insulin biosimilar to help manage blood sugar in people with diabetes, including children and adults. The product, called Merilog ...

According to the FDA, more than 38 million people in the United States have been diagnosed with diabetes, and approximately 8.4 million Americans rely on insulin therapy, either rapid-acting or ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...

It is the first biosimilar of a rapid-acting insulin product – used to control the blood glucose spike after meals – and only the third insulin biosimilar to be approved in the US. Novo ...

Last September, Tandem's t:slim X2 insulin pump, which utilises Control-IQ technology, was approved for use with Eli Lilly's ultra-rapid-acting insulin, Lyumjev, in the European Union. "FDA clears ...

Three main groups of insulin are available. Rapid-acting insulin analogs: These take between 10 and 20 minutes to have an effect. However, the size of the dose affects the duration. Assuming that ...

FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.